Amgen Inc (NASDAQ:AMGN)

162.59
Delayed Data
As of Mar 27
 +2.04 / +1.27%
Today’s Change
108.20
Today|||52-Week Range
173.14
+2.07%
Year-to-Date
Biotech, Chips Stand Their Ground; Be Careful What You Wish For: Jim Cramer's Best Bl...
Mar 28 / TheStreet.com
The Fibocall: Amgen
Mar 23 / TheStreet.com
3 Top Stocks for Obamacare Lovers
Mar 28 / MotleyFool.com
The Seven Pillars of Healthcare Strength
Mar 23 / TheStreet.com
5 Freakishly Expensive Cancer Drugs
Mar 28 / MotleyFool.com
The Sever Pillars of Healthcare Strength
Mar 23 / TheStreet.com
Could These Experimental Drugs Eclipse Harvoni's Historic Launch?
Mar 28 / MotleyFool.com
Nearly 75% Of Biotechs Have No Earnings
Mar 22 / Investing Channel
Why Investors Might Want To Stay Away From The Biotech ETF
Mar 27 / Benzinga
Dividend Stocks: 2 to Avoid, 1 to Buy
Mar 21 / MotleyFool.com
Biogen Inc, Gilead Sciences, Inc., Amgen, Inc., Celgene Corporation: Are We In A Biot...
Mar 27 / Investing Channel
Drug Spending Is Soaring: 3 Takeaways You Can't Miss
Mar 21 / MotleyFool.com
Biotech, Chips Stand Their Ground
Mar 27 / TheStreet.com
Can This Biotech Stock Go from Good to Great?
Mar 19 / MotleyFool.com
Are We In A Biotech Bubble? You Decide
Mar 27 / Investing Channel
The Zacks Analyst Blog Highlights: Amgen, Regeneron, Nektar, ACADIA and Pharmacyclics...
Mar 19 / Zacks.com
The Zacks Analyst Blog Highlights: Biogen, Prothena, Vertex, Gilead and Amgen - Press...
Mar 26 / Zacks.com
Esperion Soars on Positive Phase IIb Data on ETC-1002 - Analyst Blog
Mar 18 / Zacks.com
'Fast Money' Recap: The 3 Reasons Stocks Tanked Wednesday
Mar 26 / TheStreet.com
Regeneron Hits a 52-Week High on Positive Praluent Data - Analyst Blog
Mar 18 / Zacks.com
Selloff in Biotech Continues; Should You Worry About Tech Sector?
Mar 25 / TheStreet.com
Biotech Stock Roundup: Amgen & Regeneron Shine at ACC, Nektar Drug Disappoints - Anal...
Mar 18 / Zacks.com
Biotech Stock Roundup: Biogen Soars on Alzheimer's Data, Gilead HCV Drugs Label Updat...
Mar 25 / Zacks.com
Zacks Industry Outlook Highlights: Orexigen, MannKind, Amgen, Medivation and Express ...
Mar 18 / Zacks.com
Why Yellen & The Feds Are Bubble Blind - They Apparently Believe Wall Street's EPS Sc...
Mar 24 / Investing Channel
Pharma Stock Outlook: Let's Make a Deal - Industry Outlook
Mar 17 / Zacks.com
Stock Market News for March 24, 2015 - Market News
Mar 24 / Zacks.com
Pharma Stock Outlook: Let's Make a Deal - Zacks Analyst Interviews
Mar 17 / Zacks.com
'Fast Money' Recap: Stay Away From Biotech for at Least a Month
Mar 24 / TheStreet.com
Stock Market News for March 17, 2015 - Market News
Mar 17 / Zacks.com
Amgen Seeks Approval for PCSK9 Inhibitor Repatha in Japan - Analyst Blog
Mar 23 / Zacks.com
Where Is Radius Health Now?
Mar 17 / MotleyFool.com
The Fibocall on Amgen Generating Long-Term Overbought Condition
Mar 23 / TheStreet.com
Regeneron/Sanofi's PCSK9 Drug Praluent Data Published - Analyst Blog
Mar 16 / Zacks.com
How Lilly and Amgen Are Going in Opposite Directions
Mar 23 / TheStreet.com
Amgen Presents Encouraging PCSK9 Inhibitor Repatha Data - Analyst Blog
Mar 16 / Zacks.com
11 Promising New Drugs Expected to Make Billions in Sales
Mar 23 / TheStreet.com
Zacks Investment Ideas feature highlights: Biogen, Amgen, SPDR S&P Biotech ETF, BioSh...
Mar 16 / Zacks.com
Jim Cramer Digs Into Dozens of Charts, Finds 7 Pillars of Health Care Strength
Mar 23 / TheStreet.com
Pharma sector hails 'sea change' in heart disease treatment
Mar 15 / FT.com
Apple climbs after $1tn valuation call
Mar 23 / FT.com
1 Expensive Biotech Stock Worth Buying
Mar 15 / MotleyFool.com
Why ImmunoGen Inc. is Soaring Higher Today
Mar 23 / MotleyFool.com
Should Gilead Sciences Inc.bs Slowing Growth Concern Investors?
Mar 15 / MotleyFool.com
This Market Could Grow 6250% in 10 Years
Mar 23 / MotleyFool.com
US regulators approve first copycat biological drug
Mar 06 / FT.com
The 7 Pillars of Healthcare Strength
Mar 23 / TheStreet.com
Centerview builds record on pharma deals
Mar 05 / FT.com

To view my watchlist

Not a member yet?

Sign up now for a free account